Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Inventory (2020 - 2025)

Celularity (CELU) has disclosed Inventory for 6 consecutive years, with $571000.0 as the latest value for Q4 2025.

  • For Q4 2025, Inventory fell 89.44% year-over-year to $571000.0; the TTM value through Dec 2025 reached $571000.0, down 89.44%, while the annual FY2025 figure was $571000.0, 89.44% down from the prior year.
  • Inventory hit $571000.0 in Q4 2025 for Celularity, down from $2.6 million in the prior quarter.
  • Across five years, Inventory topped out at $24.7 million in Q2 2022 and bottomed at $571000.0 in Q4 2025.
  • Average Inventory over 5 years is $6.5 million, with a median of $5.4 million recorded in 2022.
  • On a YoY basis, Inventory climbed as much as 67.44% in 2025 and fell as far as 89.44% in 2025.
  • Celularity's Inventory stood at $9.5 million in 2021, then crashed by 44.41% to $5.3 million in 2022, then increased by 8.38% to $5.8 million in 2023, then fell by 5.98% to $5.4 million in 2024, then tumbled by 89.44% to $571000.0 in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $571000.0, $2.6 million, and $4.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.